Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neuphoria Therapeutics ( (NEUP) ) has shared an announcement.
On October 25, 2025, Neuphoria Therapeutics‘ Board of Directors declared a dividend of rights to purchase Series A Preferred Stock for each common stock share, effective October 27, 2025. The company adopted a stockholder rights plan to prevent hostile takeovers, triggered if an entity acquires 15% or more of common stock without board approval. This plan aims to protect stockholder investments and ensure fair participation in strategic reviews, while not hindering potential beneficial acquisition proposals.
The most recent analyst rating on (NEUP) stock is a Hold with a $2.30 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
More about Neuphoria Therapeutics
Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders. The company was advancing its lead drug candidate, BNC-210, for treating social anxiety disorder and post-traumatic stress disorder, but halted its development following a Phase 3 trial setback. Neuphoria also partners with Merck & Co. for early-stage clinical trials targeting cognitive deficits in Alzheimer’s disease.
Average Trading Volume: 1,438,359
Technical Sentiment Signal: Sell
Current Market Cap: $14.71M
Find detailed analytics on NEUP stock on TipRanks’ Stock Analysis page.